CJC-1295 and Ipamorelin: Two Receptors, One Vial, and What the Preclinical Record Supports
Most peptides in a research catalog are studied alone. This one is not. CJC-1295 and Ipamorelin are ordered together because the question investigators are asking is a combination question: what happens to somatotroph output when two structurally unrelated molecules, acting through two different receptors, arrive at the anterior pituitary at the same time?
That question has a real experimental literature behind it, and it is older than either molecule. It also has a specific practical consequence for US laboratories, which is that the two compounds are frequently supplied co-formulated in a single lyophilized vial rather than as two separate vials. A co-formulated blend is one product on one certificate of analysis. That changes what you should be checking before the vial goes into the freezer, and it is where this article ends.
Two receptors, two signaling routes
The somatotroph — the growth-hormone-secreting cell of the anterior pituitary — carries at least two distinct receptors relevant here.
The first is the GHRH receptor, a class B G-protein-coupled receptor that couples to Gs. Occupancy raises intracellular cAMP and activates protein kinase A, which drives both the release of stored GH and the transcription of new GH message. CJC-1295 is a modified analog of the biologically active 1–29 fragment of human GHRH, and it engages this receptor.
The second is GHS-R1a, the growth hormone secretagogue receptor, cloned by Howard and colleagues (1996, Science) from pituitary and hypothalamic tissue. GHS-R1a couples predominantly to Gq/11, activating phospholipase C, generating inositol trisphosphate, and mobilizing calcium from intracellular stores. Its endogenous ligand was identified three years later by Kojima and colleagues (1999, Nature) as ghrelin, an acylated peptide of gastric origin. Ipamorelin is a synthetic pentapeptide agonist at this receptor.
Herrington and Hille (1994, Endocrinology) made the electrophysiological case directly in isolated rat somatotropes, showing that a growth-hormone-releasing hexapeptide raised intracellular calcium by two mechanisms — release from internal stores and increased calcium entry across the membrane. Two mechanisms in one cell, distinct from the cAMP route the GHRH receptor uses.
That is the mechanistic reason a combination is interesting. The two ligands do not compete for the same site. They converge on the same secretory event by different routes.
Why the combination is not simply additive
The synergy observation predates both molecules. Cheng and colleagues (1989, Endocrinology) worked in cultured rat anterior pituitary cells and reported that the hexapeptide His-D-Trp-Ala-Trp-D-Phe-Lys-NH2 — GHRP-6, the prototype for this receptor class — produced GH release in combination with GH-releasing factor that exceeded what either agent produced alone. Bowers (1991, Endocrinology) characterized the actions of the same hexapeptide in more detail, and Sethumadhavan and colleagues (1991, Biochemical and Biophysical Research Communications) demonstrated specific, saturable binding of GHRP to rat anterior pituitary membranes — evidence for a dedicated receptor before that receptor had been cloned.
There is a second contributor beyond the pituitary. Tannenbaum (2001, Endocrine; 2003, Endocrinology) examined how secretagogues of this class interact with the hypothalamic GHRH/somatostatin oscillator that sets GH pulsatility in the rat. Somatostatin is the brake on the system. A ligand that reduces somatostatin tone while a GHRH-receptor agonist presses the accelerator produces a larger excursion than either input predicts in isolation. Wagner and colleagues (2009, Journal of Molecular Endocrinology) later proposed and tested an explicit model of how ghrelin signaling integrates with that neuroendocrine axis.
The important qualifier for anyone designing a study: the magnitude of that interaction is model-dependent, and it depends on where in the endogenous pulse cycle the challenge lands. Synergy demonstrated in dispersed pituitary cells and synergy demonstrated in an intact animal with an oscillating hypothalamus are not the same measurement.
Ipamorelin’s selectivity, which is the point of it
Ipamorelin was introduced by Raun and colleagues (1998, European Journal of Endocrinology) and characterized in rat and swine models. The finding that made it interesting was not potency — earlier secretagogues released GH perfectly well. It was selectivity. At levels producing GH release comparable to GHRP-6, Ipamorelin did not produce the accompanying rises in ACTH and cortisol that the earlier hexapeptides did.
For an experimental system, that matters a great deal. A secretagogue that also moves the hypothalamic-pituitary-adrenal axis confounds every downstream endpoint you might want to measure, because corticosteroid changes have their own effects on metabolism, immune readouts and tissue turnover. Ipamorelin’s profile in those animal models is what earned it a place in combination work.
CJC-1295, and why “which CJC-1295” is a real question
CJC-1295 exists in the literature in two forms, and conflating them is the most common error in secondary writing about it.
The molecule described by Jetté and colleagues (2005, Endocrinology) is an hGRF(1-29) analog bearing a maleimidoproprionic acid group — the Drug Affinity Complex, or DAC — which forms a covalent bond with circulating albumin. That bioconjugate was shown to activate the GRF receptor on rat anterior pituitary. Albumin conjugation extends circulating half-life by orders of magnitude relative to native GHRH(1-29), which is cleared in minutes. Alba and colleagues (2006, American Journal of Physiology: Endocrinology and Metabolism) then administered the DAC form once daily to GHRH-knockout mice and reported normalization of growth in that model — a clean demonstration in an animal whose own GHRH signal is absent.
Teichman and colleagues (2006, Journal of Clinical Endocrinology and Metabolism) published pharmacokinetic and pharmacodynamic data on the DAC form in healthy adults, reporting sustained elevation of GH and IGF-I. That is published clinical pharmacology and it is cited here as literature, not as any form of use guidance.
The material commonly sold and studied as “CJC-1295” without DAC is modified GRF(1-29) — the same 29-residue sequence with stabilizing substitutions but no albumin-binding group, and therefore a half-life measured in minutes rather than days. The two behave completely differently in a time-course experiment. A study design that assumes sustained exposure but uses the non-DAC material will produce a pulse where it expected a plateau. Confirm from the certificate of analysis and the supplier’s own sequence listing which one is in the vial, because the two are routinely sold under the same three-word name.
Downstream endpoints in animal models
GH release is a proximal readout. Where the preclinical work becomes more interesting is in what follows it. Svensson and colleagues (2000, Journal of Endocrinology) administered Ipamorelin and GHRP-6 to adult female rats and reported increases in bone mineral content — a structural endpoint, on a slower timescale, downstream of the GH/IGF-I axis rather than a direct measure of secretion.
Smith (1997, Endocrine Reviews; 2005, Endocrine Reviews) provides the two standard review treatments of this compound class and remains the sensible starting point for a literature search, including the pharmacological history that explains why so many of these molecules exist.
What the record does not establish is equally worth stating plainly. Long-duration combination exposure, receptor desensitization over repeated challenge, and the effect of the combination on the natural pulsatile architecture of GH secretion are all thinner in the literature than the acute-release data. Those are open questions, not settled ones, and a study proposing to answer them should say so rather than assume the acute finding extends.
Sourcing a blend vial in the US market
The US research-supply landscape changed materially over the past year, and laboratories that had a stable domestic supplier in 2025 have in many cases had to re-qualify one. For a co-formulated product, re-qualification has a wrinkle that single-compound vials do not.
A blend is one vial containing two compounds. That means:
- The COA must resolve both components. A single purity figure with no indication of which peak is which tells you nothing about the ratio actually present. Look for chromatographic separation of the two species and identity confirmation by mass spectrometry for each.
- The stated ratio must appear somewhere. A 10mg blend is not self-describing. Two compounds at unequal mass fractions behave nothing like a 1:1 preparation, and the ratio is a study variable.
- The batch on the vial must match the batch on the certificate. This is the check most often skipped and the one that invalidates the most work.
- The GHRH analog’s identity must be explicit — DAC or non-DAC, per the section above.
Maple Research Labs publishes a batch certificate of analysis for every catalog item, including the CJC-1295/Ipamorelin Blend 10mg, and does not list a product without one. Orders ship domestically from the Santa Barbara facility, same-day on business days, which for a lyophilized peptide is a straightforward advantage: shorter transit means fewer hours in an uncontrolled thermal environment and no customs hold sitting in the middle of the chain. The company operates as a Wyoming entity and sells only within the United States. Access is restricted to 21+.
Handling notes
Lyophilized material is stable at -20°C, and colder is better for long holds. Reconstituted material should be treated as having a short usable window under refrigeration, and repeated freeze-thaw cycles should be avoided — aliquot instead. Peptides at low concentration adsorb measurably to glass and untreated polypropylene, which biases the low end of a concentration series if it is not controlled for. Record the batch number in the notebook alongside the experiment; a result you cannot trace to a lot and a certificate is a result you cannot defend later.
All products supplied by Maple Research Labs are for research use only. These materials are not for human use, are not for veterinary use, are not for consumption, and are not intended to diagnose, treat, or prevent any condition. They are sold exclusively to qualified researchers and institutions for in vitro and laboratory investigation. Nothing on this page describes or endorses administration to people.